Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

Summary

Background Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients with metastatic urothelial cancers, including complete remissions in patients with chemotherapy refractory disease. Although mutation load and PD-L1 immune cell (IC) staining have been associated with response, they lack sufficient sensitivity and specificity for clinical use. Thus, there is a need to evaluate the peripheral blood immune environment and to conduct detailed analyses of mutation load, predicted neoantigens, and immune cellular infiltration in tumors to enhance our understanding of the biologic underpinnings of response and resistance. Methods and findings The goals of this study were to (1) evaluate the association of mutation load and predicted neoantigen load with therapeutic benefit and (2) determine whether intratumoral and peripheral blood T cell receptor (TCR) clonality inform clinical outcomes in urothelial carcinoma treated with atezolizumab. We hypothesized that an elevated mutation load in combination with T cell clonal dominance among intratumoral lymphocytes prior to treatment or among peripheral T cells after treatment would be associated with effective tumor control upon treatment with anti-PD-L1 therapy. We performed whole exome sequencing (WES), RNA sequencing (RNA-seq), and T cell receptor sequencing (TCR-seq) of pretreatment tumor samples as well as TCR-seq of matched, serially collected peripheral blood, collected before and after treatment with atezolizumab. These parameters were assessed for correlation with DCB (defined as progression-free survival [PFS] >6 months), PFS, and overall survival (OS), both alone and in the context of clinical and intratumoral parameters known to be predictive of survival in this disease state. Patients with DCB displayed a higher proportion of tumor-infiltrating T lymphocytes (TIL) (n = 24, Mann-Whitney p = 0.047). Pretreatment peripheral blood TCR clonality below the median was associated with improved PFS (n = 29, log-rank p = 0.048) and OS (n = 29, log-rank p = 0.011). Patients with DCB also demonstrated more substantial expansion of tumor-associated TCR clones in the peripheral blood 3 weeks after starting treatment (n = 22, Mann-Whitney p = 0.022). The combination of high pretreatment peripheral blood TCR clonality with elevated PD-L1 IC staining in tumor tissue was strongly associated with poor clinical outcomes (n = 10, hazard ratio (HR) (mean) = 89.88, HR (median) = 23.41, 95% CI [2.43, 506.94], p(HR > 1) = 0.0014). Marked variations in mutation loads were seen with different somatic variant calling methodologies, which, in turn, impacted associations with clinical outcomes. Missense mutation load, predicted neoantigen load, and expressed neoantigen load did not demonstrate significant association with DCB (n = 25, Mann-Whitney p = 0.22, n = 25, Mann-Whitney p = 0.55, and n = 25, Mann-Whitney p = 0.29, respectively). Instead, we found evidence of time-varying effects of somatic mutation load on PFS in this cohort (n = 25, p = 0.044). A limitation of our study is its small sample size (n = 29), a subset of the patients treated on IMvigor 210 (NCT02108652). Given the number of exploratory analyses performed, we intend for these results to be hypothesis-generating. Conclusions These results demonstrate the complex nature of immune response to checkpoint blockade and the compelling need for greater interrogation and data integration of both host and tumor factors. Incorporating these variables in prospective studies will facilitate identification and treatment of resistant patients.

Key Points

• 1Elevated mutation load correlates with better responses to PD-L1 blockade therapy
• 2T cell receptor clonality is a significant predictor of clinical outcomes
• 3Patients with higher T cell clonal diversity experienced longer survival
• 4The study's findings highlight the need to consider immune responses alongside tumor characteristics in future research
• 5Small sample size limits the generalizability of the results but provides valuable insights for further exploration.

Related articles

• Evaluating large language models for clinical note processing: local fine-tuning and internal-external validation using electronic health records from South Asia

  This research paper evaluates the effectiveness of large language models for processing clinical notes from electronic health records in South Asia, focusing on local fine-tuning and validation. It discusses the potential application of LLMs in clinical settings, particularly in resource-limited environments.

• Cardiac Cycle & Physiology: Understanding Cardiac Function

  This document provides a detailed overview of cardiac physiology, including the cardiac cycle, blood flow processes, and the cardiac conduction system. It aims to inform readers about the mechanics of the heart and its role in circulation.

• Cardiac Cycle & Physiology

  This document provides a comprehensive overview of cardiac cycle phases, blood flow through the heart, and the electrophysiology of cardiac conduction. It details the processes of deoxygenation and oxygenation of blood and the physiological aspects of cardiac output and common cardiovascular assessment findings.

• The Dual Pillars of Clinical and Community Care

  This document provides an in-depth examination of nutritional assessment and surveillance in clinical and community settings, offering guidelines on measuring malnutrition indicators and the importance of dietary interventions.

• Cather Simpson Lecture Research Brief Inaugural David Breen

  Cather Simpson Lecture Research Brief Inaugural David Breen Lecture | 14 October 2026 | 12 pm to 1 pm | AM103 The "Nespresso" of Diagnostics: Centrifugal Microfluidics for Point-of-Care Diagnostics; “Can we